Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Meningococcal vaccine Stories

2014-03-18 12:32:29

LONDON, March 18, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis World Adult Vaccines Market - Market OverviewFor much of the 20th century, vaccines were a pharmaceutical success story largely associated with children. Aggressive immunization programs eradicated Polio and Smallpox among developed nations and nearly eliminated Mumps, Pertussis, Measles,...

2014-02-26 16:26:17

TORONTO, Feb. 26, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY: Novartis announced today that Bexsero® (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) is now available to doctors and pharmacists across Canada. The vaccine is approved for use in individuals from two months through 17 years of age in Canada. Infants, toddlers and adolescents are at the greatest risk of meningococcal serogroup B (MenB) infection....

2014-02-26 08:28:23

DORVAL QC, Feb. 26, 2014 /CNW/ - Novartis announced today that Bexsero(®) (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) is now available to doctors and pharmacists across Canada. The vaccine is approved for use in individuals from two months through 17 years of age in Canada. Infants, toddlers and adolescents are at the greatest risk of meningococcal serogroup B (MenB) infection.(1) Bexsero(®) is the first broad-coverage vaccine to help protect against MenB...

2014-02-24 08:28:29

- FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada CAMBRIDGE, Mass., Feb. 24, 2014 /PRNewswire/ -- Novartis announced today that its meningococcal serogroup B (MenB) vaccine, Bexsero(®) (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), will be used as part of a vaccination program at the University of California Santa Barbara (UCSB) that began today and will end on March 7....

2013-12-26 08:23:12

LONDON, Dec. 26, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Meningitec (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Meningitec (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 SummaryMeningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these...

2013-12-26 08:23:10

LONDON, Dec. 26, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Nimenrix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Nimenrix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 SummaryMeningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons...

2013-12-26 08:23:07

LONDON, Dec. 26, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 SummaryMeningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the...

2013-12-19 16:27:31

LONDON, Dec. 19, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report:PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022SummaryGlobalData has released its new Country report, "PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022". Meningococcal disease is an acute infection caused by the gram-negative...

2013-12-19 16:27:25

LONDON, Dec. 19, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report:PharmaPoint: Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022PharmaPoint: Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022SummaryGlobalData has released its new Country report, "PharmaPoint: Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022". Meningococcal disease is an acute infection caused by the gram-negative bacterium...

Molecular Biomarkers Of Vaccine Immunity Identified
2013-12-16 12:33:15

Emory University Testing the efficacy of vaccines in clinical trials takes years, even decades. Yet challenging infections like HIV, malaria and dengue are striking today. To speed up vaccine testing, scientists at the Emory Vaccine Center have established a goal of creating a “vaccine gene chip.” This device could read the activity of all the genes in the genome in white blood cells within a few days of administration of a test vaccine. Reading such “molecular signatures” would...